Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292473540> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4292473540 endingPage "148878" @default.
- W4292473540 startingPage "148878" @default.
- W4292473540 abstract "Due to its important role in regulating angiogenesis, vascular homeostasis and remodeling, and arteriogenesis in blood vascular and lymphatic endothelial cells, VEGFR2 stimulation has demonstrated promise in preclinical studies as an endovascular treatment for ischemic myocardial and peripheral disease. However, the short half-life of protein- and cytokine-based strategies and transduction inefficiency of vector-based modalities have hindered its clinical therapeutic applications. In the present study, we used a streamlined bioinformatics strategy combining ligand-based pharmacophore development and validation, virtual screening, and molecular docking to identify agnuside, a non-toxic, natural small molecule extract of Vitex agnus-castus possessing strong binding affinity, druggable physiochemical properties, and conformationally stable hydrogen bond and hydrophobic interactions with catalytically important residues within VEGFR2's active and allosteric sites. In-vitro proliferation, tube formation, and scratch wound migration assays provide evidence that agnuside promotes endothelial cell angiogenesis. Agnuside increases HUVEC proliferation with an EC50 of 1.376 μg/mL, stimulates tubulogenesis dose-dependently, and increases scratch wound migration rate. An additional angiogenesis assay suggests that agnuside may actively compete with a VEGFR2 inhibitor for VEGFR2 binding site occupancy to increase total length and branching length of HUVEC tubular networks. Chemometric analysis of molecular interaction fields (MIFs) by partial least squares (PLS)-derived quantitative structure activity relationship (QSAR) analysis and MIF contours provides the framework for the formulation of agnuside analogues possessing greater potency. Our research supports that agnuside may be a lead molecule for therapeutic angiogenesis." @default.
- W4292473540 created "2022-08-21" @default.
- W4292473540 creator A5001687552 @default.
- W4292473540 creator A5017705025 @default.
- W4292473540 creator A5031495335 @default.
- W4292473540 creator A5057433492 @default.
- W4292473540 creator A5065278268 @default.
- W4292473540 creator A5065320630 @default.
- W4292473540 date "2022-09-01" @default.
- W4292473540 modified "2023-10-16" @default.
- W4292473540 title "The F1Fo-ATPase inhibitor IF1 promotes proliferation of anoxic cancer cell upon reoxygenation" @default.
- W4292473540 doi "https://doi.org/10.1016/j.bbabio.2022.148878" @default.
- W4292473540 hasPublicationYear "2022" @default.
- W4292473540 type Work @default.
- W4292473540 citedByCount "0" @default.
- W4292473540 crossrefType "journal-article" @default.
- W4292473540 hasAuthorship W4292473540A5001687552 @default.
- W4292473540 hasAuthorship W4292473540A5017705025 @default.
- W4292473540 hasAuthorship W4292473540A5031495335 @default.
- W4292473540 hasAuthorship W4292473540A5057433492 @default.
- W4292473540 hasAuthorship W4292473540A5065278268 @default.
- W4292473540 hasAuthorship W4292473540A5065320630 @default.
- W4292473540 hasBestOaLocation W42924735401 @default.
- W4292473540 hasConcept C103697762 @default.
- W4292473540 hasConcept C159110408 @default.
- W4292473540 hasConcept C161624437 @default.
- W4292473540 hasConcept C166342909 @default.
- W4292473540 hasConcept C170493617 @default.
- W4292473540 hasConcept C185592680 @default.
- W4292473540 hasConcept C2780394083 @default.
- W4292473540 hasConcept C41685203 @default.
- W4292473540 hasConcept C502942594 @default.
- W4292473540 hasConcept C55493867 @default.
- W4292473540 hasConcept C56173144 @default.
- W4292473540 hasConcept C71924100 @default.
- W4292473540 hasConcept C86803240 @default.
- W4292473540 hasConcept C95444343 @default.
- W4292473540 hasConcept C98274493 @default.
- W4292473540 hasConceptScore W4292473540C103697762 @default.
- W4292473540 hasConceptScore W4292473540C159110408 @default.
- W4292473540 hasConceptScore W4292473540C161624437 @default.
- W4292473540 hasConceptScore W4292473540C166342909 @default.
- W4292473540 hasConceptScore W4292473540C170493617 @default.
- W4292473540 hasConceptScore W4292473540C185592680 @default.
- W4292473540 hasConceptScore W4292473540C2780394083 @default.
- W4292473540 hasConceptScore W4292473540C41685203 @default.
- W4292473540 hasConceptScore W4292473540C502942594 @default.
- W4292473540 hasConceptScore W4292473540C55493867 @default.
- W4292473540 hasConceptScore W4292473540C56173144 @default.
- W4292473540 hasConceptScore W4292473540C71924100 @default.
- W4292473540 hasConceptScore W4292473540C86803240 @default.
- W4292473540 hasConceptScore W4292473540C95444343 @default.
- W4292473540 hasConceptScore W4292473540C98274493 @default.
- W4292473540 hasLocation W42924735401 @default.
- W4292473540 hasOpenAccess W4292473540 @default.
- W4292473540 hasPrimaryLocation W42924735401 @default.
- W4292473540 hasRelatedWork W2045193453 @default.
- W4292473540 hasRelatedWork W2058925182 @default.
- W4292473540 hasRelatedWork W2112883272 @default.
- W4292473540 hasRelatedWork W2136206204 @default.
- W4292473540 hasRelatedWork W2318344963 @default.
- W4292473540 hasRelatedWork W2756495142 @default.
- W4292473540 hasRelatedWork W2809125516 @default.
- W4292473540 hasRelatedWork W3133700351 @default.
- W4292473540 hasRelatedWork W4220821743 @default.
- W4292473540 hasRelatedWork W4386271327 @default.
- W4292473540 hasVolume "1863" @default.
- W4292473540 isParatext "false" @default.
- W4292473540 isRetracted "false" @default.
- W4292473540 workType "article" @default.